TORONTO, Sept. 20, 2012 /CNW/ - Amorfix Life Sciences Ltd. announced today that the Company is
collaborating with Dr. Dawn Waterhouse from the BC Cancer Agency and
the University of British Columbia to test the Company's tumor specific
antibodies in animal models of ovarian cancer. "This is a significant
milestone for our novel cancer programs and will establish the proof of
concept for our lead misfolded prion protein antibody project" said
Amorfix President and CEO, Dr. Robert Gundel. "We have already
demonstrated tumor specific binding of our antibody and potent ovarian
tumor cell killing with an antibody-toxin conjugate in a number of
cellular assays. We have now initiated a very ambitious series of
studies in a number of ovarian cancer models. These studies represent
an exciting next step to demonstrate the ability to generate a new
generation of specific tumor binding antibodies that effectively
inhibit tumor growth while leaving healthy cells untouched, in an
animal model of cancer."
The Company used its proprietary ProMIS™ Discovery technology to
identify novel, disease specific epitopes (DSEs) and generate a lead
candidate antibody against an epitope that is exposed only on the
surface of misfolded prion protein and not on the normally folded
protein. Initial studies demonstrated that misfolded prion protein is
expressed on the cell surface of ovarian tumor cells and that the
antibody selectively binds to tumor cells and not to normal cells,
including normal ovarian cells. The studies conducted in collaboration
with Dr. Waterhouse will evaluate the ability of the antibody to
effectively reduce tumor growth in animal models of ovarian cancer.
The antibody will be tested in two different models of ovarian cancer,
and will be tested for efficacy both on its own and when conjugated to
About Ovarian Cancer
Ovarian cancer is the fifth most common cancer among women, and it
causes more deaths than any other type of female reproductive cancer.
Most deaths from ovarian cancer occur in women age 55 and older.
Ovarian cancer is often not diagnosed until late-stage disease when the
cancer has spread to other organs in the body, which contributes to the
short survival time following diagnosis. Ovarian cancer is typically
treated with surgery and chemotherapy. Chemotherapy is not very
effective as a treatment and is associated with a number of potential
dose-limiting side effects due to its non-specific killing of both
tumor and normal cells.
Amorfix Life Sciences Ltd. (TSX:AMF) is an early-stage product
development company developing therapeutic antibodies and diagnostics
targeting misfolded protein diseases. Amorfix utilizes its
computational discovery platform, ProMIS™, to predict novel Disease
Specific Epitopes (DSEs) on the molecular surface of misfolded
proteins. Using this technology, Amorfix is developing novel antibody
therapeutics and companion diagnostics for cancer and amyotrophic
lateral sclerosis (ALS). In addition, Amorfix has developed two
proprietary technologies to specifically identify very low levels of
misfolded proteins in a biological sample: Epitope Protection™ and
AMFIA™, an ultra-sensitive dual-bead immunoassay. Use of these
technologies has generated a cerebrospinal fluid (CSF) screening test
for Alzheimer's disease (AD) and mild cognitive impairment (MCI), and
an ultrasensitive method for detecting the hallmark of AD, aggregated
beta-Amyloid, in brain tissue, CSF and blood from animal models of AD.
For more information about Amorfix, visit www.amorfix.com.
The TSX has not reviewed and does not accept responsibility for the
adequacy or accuracy of this release.
This news release contains certain forward-looking information, which
involves known and unknown risks, uncertainties and other factors that
may cause actual results, performance or achievements to be materially
different from those implied by statements herein, and therefore these
statements should not be read as guarantees of future performance or
results. All forward-looking statements are based on the Company's
current beliefs as well as assumptions made by and information
currently available to it, such as the commitments of potential
subscribers that are not binding legal obligations, as well as other
factors, that are subject to change. Readers are cautioned not to
place undue reliance on these forward-looking statements, which speak
only as of the date of this press release. Due to risks and
uncertainties, including the risks and uncertainties identified by the
Company in its public securities filings, actual events may differ
materially from current expectations. The Company disclaims any
intention or obligation to update or revise any forward-looking
statements, whether as a result of new information, future events or
otherwise, unless required by law.
ProMIS™, Epitope Protection™ and AMFIA™ are trademarks of Amorfix Life
SOURCE: Amorfix Life Sciences Ltd.
For further information:
Dr. Robert Gundel
President and Chief Executive Officer
Amorfix Life Sciences Ltd.
Tel: (416) 847-6957
Fax: (416) 847-6899
Chief Financial Officer
Amorfix Life Sciences Ltd.
Tel: (416) 847-6926
Fax: (416) 847-6899